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Aim. The objective of the present study was to test the safety of supplementation with the American ginseng (AG) interventional
material as an adjunct to conventional therapy (diet and/or medications) in type 2 diabetes, using a double-blind, randomized,
placebo-controlled, parallel design. Methods. Each participant received either AG (10% ginsenosides) or placebo capsules
(500mg/meal = 3 g/day) for a period of 12 weeks. Outcomes included measures of safety including kidney function (urates and
creatinine), liver function (AST and ALT), and haemostatic function (PV and INR). Results. Seventy-four participants with well-
controlled type 2 diabetes (sex: 28M and 46 F, age: 63± 9.5, BMI: 32± 5, and HbA1c: 7± 1.3), randomized to either intervention
(𝑛 = 35) or control (𝑛 = 39) group, completed the study. There was no change in any of the measures of safety between
treatments from baseline. The number or severity of adverse events did not differ between the AG intervention and placebo.
Conclusion. Following 12 weeks of supplementation with AG, safety was not compromised in a high cardiovascular disease (CVD)
risk population of patients with type 2 diabetes. This demonstrated that safety is noteworthy, as reviews have continuously warned
of possible adverse effects of ginseng consumption.
1. Introduction
Despite recent advances in pharmotherapy and disese man-
agement, diabetes mellitus continues to be an important
public health concern, affecting ∼382 million persons in the
world [1]. Glycemic management in type 2 diabetes mellitus
(T2DM) has become increasingly complex with a widening
array of hypoglycemic agents available used as polypharmacy,
mounting concerns about their potential interaction and
associated adverse effects [2]. At the same time, the care of
patients with T2DM has become influenced by a growing
interest in complementary and alternative medicine (CAM)
includingmedicinal herbs [3–6]. One of the most promissing
therpeutic herbals seems to be the American ginseng.
According to Barnes et al., 14.1% of US adults who used
natural health products (NHP) reported ginseng use, making
it the fifth most commonly used herbal supplement [7]. This
is significant given that 17.7% of the US population uses
some form of NHPs for disease prevention or treatment (7).
Besides efficacy, in order to obtain a balanced assessment
of the clinical application potential of ginseng, it is crucial
to consider its safety profile. The available data suggest that
ginseng is well tolerated by most users, with the most fre-
quently experienced adverse effects beingmild and reversible
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[6, 8]. Moreover, various animal studies and randomized
controlled trials showed that Panax ginseng (Asian ginseng)
and Panax quinquefolius (American ginseng), the two most
commonly consumed species of ginseng, exert a neutral or
lowering effect on blood pressure [9, 10], thus contrasting
Siegel’s finding since 1979 [11].
It has previously been stated that until solid evidence is
available which demonstrates the safety of specific alternative
medicine interventions uncritical acceptance of untested and
unproven alternativemedicine therapies should proceedwith
caution [12]. Therefore, to address the paucity of randomized
clinical studies assessing ginseng on long-term outcomes in
T2DM, we assessed the safety parameters of 12 weeks of
supplementation with the American ginseng that in the same
study demonstrated positive health benefits, taken in the
context of its use adjunct to usual therapy in people with
T2DM.
2. Patients and Methods
Presented data represents a secondary subset analysis of
trial data evaluating effects of AG on glycemic outcome
measures (unpublished to date) and vascular outcome mea-
sures [13]. Seventy-four participants (35 interventions; 39
placebos) with well-controlled T2DM were recruited from
the diabetes outpatient clinic. Inclusion criteria encompassed
well-controlled T2DM for >6 months without manifest com-
plications and metabolically stable patients (average HbA1c
between 6.5% and 8.1%) on diet and/or conventional diabetes
therapies. In addition to diagnosed type 2 diabetes, eligi-
bility criteria included age over 40 years. Exclusion criteria
included systolic blood pressure (BP) >160mmHg or dias-
tolic BP > 100mmHg, secondary hypertension, pregnancy,
kidney or liver disease, unstable angina, use of ginseng
within 2 months prior to the initiation of the study, and a
weight fluctuation of ±2 kg during the intervention periods.
All subjects gave informed written consent before taking
part in the study, approved by the institutional ethics board
(REB number 10/2008). Research followed guidelines of the
Declaration of Helsinki and Tokyo.
Participants were randomly assigned to one of the two
interventions and received, prior to each of the main meals,
three times daily, two 500mg capsules (total 3 g/day), of either
American ginseng extract or identical-appearing placebo
capsules containing corn starch. American ginseng root
was supplied by the Ontario Ginseng Growers (Simco, ON,
Canada), combining five batches from fivemajor farms (ratio
1 : 1 : 1 : 1 : 1) to be representative of entire growing area. The
AG intervention was prepared using a conventional ethanol
extraction containing 10% total ginsenosides. The dose has
been selected based on data from the previously conducted
long-term study and derived from the acute-to-chronic
clinical testing program for AG [14]. Both interventions
were taken simultaneously with usual antihypertensive and
hypoglycaemic medications, which included maintenance
of the type and dose of such therapies in addition to
adherence to dietary recommendations. Randomization to
intervention was done using a computer-generated ran-
dom number table. Subjects, investigators, and statistician
were blinded to the identity of the placebo and ginseng
capsules by coding and by the indiscernible nature of the
capsules.
The study used a randomized, placebo-controlled,
double-blind design. The first study phase was a recruitment
phase during which interested patients were invited to the
clinic to attend an information session providing details
about the study procedure. Prospective patients were invited
back to the clinic after a 10–12 h overnight fast for screening
that included a blood sample and completion of medical
questionnaires. Patients who satisfied inclusion criteria
proceeded to the second phase where they were randomized
to either AGor placebo arm for the 12-week follow-up period.
Throughout the intervention phase, patients attended the
clinic every 6 weeks (weeks 0, 6, and 12) to have biochemical
and anthropometric measurements taken, complete IQOLA
SF-36v2 questionnaire [15], receive a new treatment batch,
return unused pills, and conduct an interview with the
dietician. Patients were advised to maintain initial body
weight and follow consistent dietary and physical activity
patterns throughout the study. They were also asked to
refrain from all medications including AG or placebo during
the preceding 12 hours prior to the study visit.
Safety was the outcome measure which included markers
of hepatic (aspartate aminotransferase (AST) and alanine
aminotransferase (ALT)), renal (serum urates and serum cre-
atinine), and haemostatic (prothrombin time (PT) and inter-
national normalized ratio (INR)) functions. Our research
group previously found that systolic blood pressure was
significantly improved during AG compared with placebo
(𝑃 < 0.001), whereas no significant between-treatment
end difference in diastolic BP (DBP) was observed [13].
Finally, body weight change from week 0 to week 12 was
not significantly different between AG and placebo and the
proportion of pills consumed over the 12 weeks did not differ
between the two groups [13].
Samples for hepatic and renal functions, as well as plasma
samples for haemostatic function, were analysed at Clinical
Department for Laboratory Diagnostics, University Hospital
Dubrava. Prothrombin time and international normalized
ratio were analyzed on BCS XP analyzer (Siemens, Marburg,
Germany). Urea, creatinine, ALT, and AST were determined
using standard methods on AU 2700 plus analyser (Beckman
Coulter, Tokyo, Japan).
Per-protocol analyses were conducted. Changes in hep-
atic, renal, and haemostatic functions, were calculated at
baseline and after 12 weeks for each intervention. The demo-
graphic findings and participant characteristics were com-
pared using a 𝑡-test for independent samples and 𝜆2 test for
the intervention and control groups. Comparison between
groups and treatment end differences in safety outcome
measures is assessed using Factorial ANOVA and Fisher LSD
test. Results were expressed as number of participants (𝑛),
mean ± SD, range (minimum–maximum), and significant
at 𝑃 < 0.05. Statistical analyses were performed using
STATISTICA v 6.1 (StatSoft Inc., USA).
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Table 1: Baseline demographic and clinical characteristics of study subjects.
Variables Group 𝑃
Intervention Control
Sample size (𝑛) 35 39
Gender (male/female) 13/22 15/24 0.907
Age (years) 61.9 ± 8.59 63.7 ± 10.28 0.447
Weight (kg) 88.1 ± 17.22 80.9 ± 15.91 0.071
BMI (kg/m2) 33.0 ± 5.53 30.1 ± 4.68 0.017
WHR (male) 0.97 ± 0.052 1.00 ± 0.048 0.282
WHR (female) (%) 0.91 ± 0.059 0.97 ± 0.065 0.052
HbA1c (%) 7.2 ± 1.31 6.9 ± 1.21 0.466
FPG (mmol/L) 8.8 ± 2.64 7.7 ± 1.97 0.043
Antihypertensive agents 35 39 0.076
Number taking 1 agent/≥2 agents 20/15 21/18
Number taking specific agents
BB (8), CCB (9), ACE
(16), ARB (0), TD (1),
𝛼-B (1), mox (2), fixed
comb. (19)#
BB (5), CCB (9), ACE
(24), ARB (2), TD (3),
𝛼-B (1), mox (2), fixed
comb. (17)#
Oral hypoglycemic agents 35 30 0.326
Number taking 1 agent/≥2 agents 10/25 16/14
Number taking specific agents
MET (25), SULF (27),
DPP-4 inh (6), GLP-1
(1), MET + TZD (1),
ACA (3)
MET (23), SULF (16),
DPP-4 inh (5), GLP-1
(0), MET + TZD (0),
ACA (1)
Hypolipemic agents 27 34 0.707
Number taking 1 agent/≥2 agents 22/5 30/4
Number taking specific agents STAT (24), FIB (7), EZE(0), fixed comb. (1)##
STAT (32), FIB (4), EZE
(1), fixed comb. (1)##
Data expressed as mean ± SD.
BMI: body mass index; WHR: waist-to-hip ratio; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose.
ACE indicates angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BB: 𝛽-blocker; CCB: calcium channel blocker; TD: thiazide
diuretic; 𝛼-B: alpha-blocker; mox: moxonidin (central alpha adrenergic agonist); MET: metformin; SULF: sulfonylurea; DPP-4 inh: dipeptidyl peptidase-4
inhibitor; GLP-1: glucagon-like peptide-1 agonist; ACA: acarbose; TZD: thiazolidinediones; STAT: statin; FIB: fibrate; EZE: ezetemibe; fixed comb.: fixed-dose
combination antihypertensives.
#ACE + D; ARB + D; ACE + CCB.
##STAT + EZE.
𝑃 value by the independent 𝑡-test or the Yates corrected chi-square test, as appropriate.
3. Results
Eighty-one participants were assessed for their eligibility
and enrolled in the study. Their flow through the study is
depicted in Figure 1. Dropouts on AG and placebo arms
were 5 and 2, respectively. Reasons for dropouts during the
protocol included change in medication therapy (𝑛 = 5) and
inability to continue (𝑛 = 2). Medication change refers to
any change in type or dosage of the antihypertensive and/or
antihyperglycemic therapy that the patients were receiving.
Two patients declined to continue for the following reasons;
one was hospitalized due to glaucoma and the other stated
lack of time for completion of the study.
Seventy-four participants (28 men and 46 women), aged
63 ± 9.5 years (mean ± SD), with type 2 diabetes, who met
the eligibility criteria and were metabolically stable (average
HbA1c: 7.1 ± 1.3% and average FPG: 8.3 ± 2.3mmol/L),
completed the study. Usual diabetes treatment received con-
comitantly by the participants was diet only (𝑛 = 9) or
diet plus oral agents (metformin, 𝑛 = 48; sulfonylurea, 𝑛 =
43; dipeptidyl peptidase-4 inhibitors, 𝑛 = 11; glucagon-like
peptide-1 agonist, 𝑛 = 1; acarbose, 𝑛 = 4; metformin +
pioglitazone, 𝑛 = 1). Analysis of baseline parameters revealed
that the two groups were comparable in all demographic and
clinical parameters. However, exception was a baseline body
mass index (BMI) and fasting plasma glucose (FPG) which
were significantly higher in the group randomized to ginseng
arm (Table 1). The proportion of pills consumed over the 12
weeks with compliance above 80% did not differ between the
two groups [13].
Within- and between-treatment differences in safety
parameters for hepatic, renal, and haemostatic functionswere
assessed and adverse effects were monitored for AG and
placebo. There was no significant dependent or independent







N = 81 screened and
N = 41 received placeboN = 40 received AG
N = 40 received AG
N = 2 excluded
Medication change (n = 2)
N = 38 received AG
N = 2 excluded
Declined to continue (n = 2)
N = 1 excluded
Medication change (n = 1)
N = 35 received AG
Weeks 0–6
Weeks 6–12
N = 41 received placebo
N = 1 excluded
Medication change (n = 1)
N = 40 received placebo
N = 1 excluded
Medication change
(n = 1)
N = 39 received placebo
Figure 1: Schematic diagram of the flow of participants through the trial exploring the effect of AG treatment on safety in type 2 diabetic
patients.
effect of treatment and time on safety parameter changes,
namely, hepatic function (AST (𝑃 = 0.107); ALT (𝑃 =
0.763)), renal function (urates (𝑃 = 0.498); creatinine
(𝑃 = 0.808)), and haemostatic function (PV (𝑃 = 0.469);
INR (𝑃 = 0.413)) (Tables 2 and 3). All values were
within the normal ranges specified by Clinical Department
for Laboratory Diagnostics, University Hospital Dubrava.
Furthermore, only one adverse event was reported during
the trial. One participant reported stomach heaviness during
the first six weeks in the AG group; however, he did not
discontinue the AG intervention. The mean absolute AST,
ALT, creatinine, urates, PV, and INR values did not differ
significantly between both interventions at baseline. There
was no effect of study period on safety parameters for hepatic,
renal, and haemostatic functions.
4. Discussion
The present study represents well-controlled, randomized,
clinical study which examined the long-term safety of a
ginseng source. Twelve weeks of supplementation with the
selected AG extract, dose (3 g/day), and mode of admin-
istration (preprandial oral agent taken at −40min) as an
adjunct to usual care in participants with type 2 diabetes
demonstrated clinical safety, as assessed by hepatic, renal, and
haemostatic functions. None of the outcome safety variables
were altered on the AG intervention compared with placebo
or baseline values.
Furthermore, the number or severity of adverse events
was not significantly different between the AG treatment and
placebo; only one adverse event was reported in the interven-
tion group.This demonstrated that safety is noteworthy as the
potential for ginseng to cause adverse events and interact with
drugs has been debated for the past few decades [16, 17].
Thewhole safety paradigm around ginseng arouse follow-
ing an observational study since 1979 where ginseng intake
in an observational study was associated with elevated BP
and several other adverse effects including gastrointestinal
disturbances, insomnia, and nervousness [11]. The adverse
effects were observed when taken at doses much higer
than the recommended dose, up to 15 g per day where the
recommended daily dose is 0.5–2 g. The validity of these side
effects is questionable due to a lack of a control group in the
study and the fact that subjects were not controlled for dose,
duration, route of administration, type of ginseng, or other
concurrent bioactive substances intake (e.g., caffeine). When
the dose was decreased to 1.7 g/day, the symptoms were rare.
Thus the only conclusion that can be validly extracted from
the Siegel study is that the excessive and uncontrolled intake
of ginseng products should be avoided [18].
Isolated case reports have suggested that Panax gin-
seng (Asian ginseng) was associated with adverse effects
ranging from insomnia, diarrhoea, vaginal bleeding, and
mastalgia to severe headache, schizophrenia, and the Stevens-
Johnson syndrome [19, 20]. Although the exact incidence
of these adverse effects is unknown, it seems to be low and
related to individual case reports. Complex terminology and
lack of clear distinction between various ginseng species,
namely, Asian (Chinese or Korean) ginseng (Panax ginseng),
American ginseng (Panax quinquefolius), and Siberian or
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Table 2: Change in AST, ALT, creatinine, urates, PT, and INR within control and AG intervention groups.
Parameter Control group (𝑛 = 39) Δ (%) Intervention group (𝑛 = 35) Δ (%)
Week 0 Week 12 Week 0 Week 12
AST (U/L) 21.1 ± 7.46 20.9 ± 7.02 0.26 (1.23) 19.6 ± 6.73 18.3 ± 4.17 1.32 (6.74)
ALT (U/L) 24.7 ± 10.95 24.7 ± 11.66 −0.04 (−0.16) 25.5 ± 12.67 23.9 ± 10.25 1.65 (6.47)
Creatinine
(𝜇mol/L) 83.78 ± 18.97 85.0 ± 15.47 −1.28 (−1.49) 82.3 ± 15.85 84.1 ± 15.49 −1.74 (−2.11)
Urates (𝜇mol/L) 309.7 ± 68.21 294.8 ± 79.26 14.9 (4.8) 314.1 ± 82.27 311.9 ± 87.49 2.2 (0.7)
PT 100.3 ± 11.53 101.2 ± 10.78 −0.93 (−0.93) 98.1 ± 8.54 98.7 ± 9.35 −0.58 (−0.59)
INR 0.9 ± 0.08 1.0 ± 0.07 −0.01 (−1.01) 1.0 ± 0.08 0.9 ± 0.05 0.04 (3.96)
Data expressed as mean ± SD.
Table 3: Between- and within-treatment change from baseline differences in AST, ALT, creatinine, urates, PT, and INR.
Parameter Control groupWeek 0 versus week 12#
Intervention group







AST (U/L) 0.868 0.409 0.331 0.107
ALT (U/L) 0.989 0.555 0.760 0.763
Creatinine (𝜇mol/L) 0.753 0.665 0.726 0.808
Urates (𝜇mol/L) 0.596 0.913 0.853 0.498
PV 0.824 0.804 0.523 0.469
INR 0.918 0.168 0.520 0.413
#Fisher LSD.
Russian ginseng (Eleutherococcus senticosus) have generated
confusion, and it needs to be emphasized that most of the
reported adverse effects pertain to Panax ginseng.
In 2002, Coon and Ernst systematically reviewed 146 clin-
ical trials representing>8500 individual exposures to ginseng
and found it having the same adverse event profile as placebo
[8]. The most common events included headache, nausea,
restlessness, and sleeplessness which were transient in nature.
Ginseng use was found to be well tolerated and its effects
were found to bemild and reversible. Furthermore, according
to the World Health Organisation (WHO) monograph on
selected medicinal plants, American ginseng root has no
contraindications and serious adverse effects associated with
its use [21].
We administered a dose of 3 g, which is the recommended
dose of ginseng in traditional Chinese medicine [22], in
alignment with a dose recommended by the Commission
E monograph and WHO ginseng monograph [23, 24] and
the average intake reported in the study by Siegel. As well,
the 12-week treatment period represented the time span in
which hypertension developed in Siegel’s report. Previously,
we found that AG intake at 3 g/day for 12 weeks relative
to placebo was associated with a decreasing effect on BP
in hypertensive and type 2 diabetic individuals [13]. Stavro
et al. reported that hypertensive individuals who choose to
consume North American ginseng should be aware of its
overall safety and its neutral effect on BP [9].
Several caveats limit the study interpretation. First, the
results may not be generalizable to other sources of AG,
including the unprocessed root or any other ginseng extracts.
It was recently demonstrated that the ginsenoside composi-
tion is highly variable [25] and that similar experimentally
simulated variability may contribute to equally high vari-
ability in its efficacy and safety across batches [26]. This is
compounded by the absence of efficacy and safety based
standardization. Finally, the absence of follow-up data in
the dropouts precluded intention-to-treat analyses to further
support the interpretation of the data.
5. Conclusion
In conclusion, the selected AG treatment generated rather
convincing long-term clinical safety when administered as
an adjunct to conventional antihypertensive and antidiabetic
therapy. The present study demonstrates that AG did not
alter any of the studied safety parameters, namely, renal,
hepatic, or haemostatic function.This answers the call posed
by the medical establishment for more randomized placebo-
controlled clinical studies and provides evidence that ginseng
does not cause anymore adverse events than placebo. Further
long-term studies with different types of ginseng and larger
sample size are needed before recommendations are made
with regard to its safety.
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